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Abstract
Aim: Type 2 diabetes mellitus (T2DM) is associated with an increased risk of cardio-
vascular disease (CVD) linked to atherogenic dyslipidaemia and postprandial hyper-
lipidaemia. Alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9)
inhibitor, improves CVD risk by reducing the concentration of low-density
lipoprotein-cholesterol (LDL-C). However, effects of PCK9 inhibitors on other aspects
of diabetic dyslipidaemia, particularly in the postprandial situation, are less clear.
Material and Methods: Twelve male patients with T2DM on an intensive insulin regi-
men completed a 6-week randomized, double-blind, placebo-controlled, proof-of-
concept study. Participants received three biweekly dosages of subcutaneous
alirocumab (150 mg) or placebo. Before and after the intervention, fasting and post-
prandial triglyceride (TG) plasma levels, apolipoprotein (apo) B48, lipoprotein compo-
sition isolated by ultracentrifugation, vascular function and markers of inflammation
were evaluated.
Results: Alirocumab treatment reduced fasting plasma TG levels (between group
median change −24.7%; P = 0.018) and fasting apoB48 serum levels (−35.9%;
P = 0.039) compared with placebo. Alirocumab reduced the plasma TG area under
the curve (AUC) (−26.4%; P = 0.006) and apoB48 AUC (−55.7%; P = 0.046), as well
as plasma TG incremental AUC (−21.4%; P = 0.04) and apoB48 incremental AUC
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(−26.8%; P = 0.02). In addition, alirocumab reduced fasting and postprandial TG levels
in very low-density lipoprotein (VLDL) and LDL. Alirocumab improved fasting pulse
wave velocity, but no changes in postprandial markers of inflammation were
observed.
Conclusions: In addition to the well-known LDL-C-reducing effects, 6 weeks of
alirocumab treatment lowered both fasting and postprandial plasma TG levels by
reducing the TG levels in VLDL and LDL and the concentration of intestinal
remnants.
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1 | INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a major global health problem
associated with an increased risk of cardiovascular disease (CVD).1,2
Despite advances in the treatment of diabetes and interventions
aimed at reducing CVD risk factors,3,4 patients with T2DM still have
an unacceptable residual CVD risk compared with the general popula-
tion.5 One of the metabolic complications in diabetes is a cluster of
atherogenic lipid abnormalities, characterized by elevated levels of
plasma triglycerides (TG), reduced concentrations of high-density
lipoprotein-cholesterol (HDL-C), increased small dense low-density
lipoprotein-cholesterol (LDL-C) and postprandial hyperlipidaemia,
including accumulation of atherogenic chylomicron remnants.6,7
Postprandial hyperlipidaemia has been associated with an
increased risk of CVD.8-10 In addition, evidence for a connection with
a systemic inflammatory response by activation of circulating
leucocytes and the generation of cytokines has been reported.11-14
Furthermore, this postprandial hyperlipidaemia also has been associ-
ated with impaired vascular function.13,15,16 Improving postprandial
hyperlipidaemia may be an important tool in reducing the residual
CVD risk present in patients with T2DM.17,18
Statins are the preferred lipid-lowering therapy in T2DM. These
drugs preferentially reduce LDL-C, but they also have a mild effect on
postprandial levels of TG and apolipoprotein (apo) B48, the structural
protein of intestinally derived chylomicrons and their remnants.19-23
Recently, a novel treatment has been introduced with proprotein con-
vertase subtilisin/kexin type 9 (PCSK9) inhibitors. Inhibition of PCKS9
with antibodies, of which alirocumab and evolocumab are currently
used in clinical practice, decreases PCSK9-mediated breakdown of the
LDL receptor (LDLR) and consequently increases hepatic LDL uptake
via apoB100 recognition,24 leading to lower levels of LDL-C in plasma.
Higher LDLR expression may also improve chylomicron and VLDL
remnant clearance via the apoE binding domain of the LDLR.25
ApoB48 lacks the carboxy terminal part of the apoB100 molecule,
which is the binding domain for the LDLR. Moreover, apoE binding to
the LDLR has a higher affinity than apoB binding.25
PCSK9 inhibitors have been shown to reduce CVD risk in various
populations, including subgroups of patients with diabetes.26,27
Furthermore, clinical trials have shown that PSCK9 inhibition
improves diabetic dyslipidaemia, by reducing LDL-C and increasing
HDL-C.28 However, the effects on TG and apoB48 have been less
clear, with the majority of studies showing only a modest effect on
fasting levels.26,27,29 Two previous studies with PCSK9 inhibitors in
healthy, normolipidaemic subjects did not show effects on postpran-
dial TG and apoB48 levels.20,29 In contrast, patients with loss of func-
tion of PCSK9 display postprandial reductions of TG and apoB48
levels.30 To date, the postprandial effects of PCSK9 inhibition in
patients with T2DM are unclear.
The present study was designed as an explorative proof-of-
concept study to investigate the effects of PCSK9 inhibition with
alirocumab on postprandial lipaemia, endothelial function and sys-
temic inflammation in patients with T2DM.
2 | MATERIALS AND METHODS
2.1 | Study design and subjects
This study was designed as a single-centre 1:1 randomized, double-
blind, placebo-controlled explorative proof-of-concept study that aimed
to compare the effect of alirocumab versus placebo on postprandial
lipaemia, endothelial function and inflammation. The study was
approved by the Institutional Review Board of the Franciscus Gas-
thuis & Vlietland, Rotterdam, the Netherlands, the regional independent
medical research ethics committee TWOR, Rotterdam, and by the
national competent authority. All patients provided written informed
consent before any specific study procedure. The study was registered
at www.trialregister.nl under clinical trial number NTR6709.
Between December 2017 and October 2018, male patients with
T2DM on intensive insulin treatment who visited the Diabetes and
Vascular Center of the Franciscus Gasthuis & Vlietland (Rotterdam,
the Netherlands) were recruited. All consecutive patients with the
required characteristics were screened. Inclusion criteria were: male
sex, ≥18 years old, diagnosis of T2DM, intensive insulin therapy
(once-daily long-acting basal insulin and three times daily short-acting
insulin, with a stable dosage for 10 weeks) and fasting plasma TG
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concentrations between 1.5 and 7.0 mmol/L. Exclusion criteria were:
smoking, decreased kidney function (estimated glomerular filtration
rate <40 mL/min/1.73 m2), a cardiovascular event, or a severe hyp-
oglycaemic event in the previous 6 months.
2.2 | Data collection
All subjects visited the hospital after a 10-h overnight fast. Anthropo-
morphic characteristics (length, body weight, body mass index, waist
circumference) and blood pressure were measured. The medical and
family histories were recorded. A fasting venous blood sample was
obtained and baseline arterial stiffness was determined after 5 min of
rest. Participants received an oral fat load consisting of fresh cream
(Albert Heijn, Zaandam, the Netherlands) in a dose of 50 g of fat per
m2 body surface.31,32 The cream contains a 40% (w/v) fat emulsion
with a polyunsaturated/saturated fat ratio of 0.10, containing 0.001%
(w/v) cholesterol and 3% (w/v) carbohydrates, representing a total
energy content of 3700 kcal/L. During the oral fat loading test, partic-
ipants were not allowed to eat or to drink (except water) and they
were asked to refrain from physical activity. Systolic and diastolic
blood pressure, arterial stiffness measurements and venous blood
sampling were repeated every 2 h until 8 h after ingestion of the
cream.
2.3 | Outcome measures
The primary endpoint was the change in postprandial TG and serum
apoB48 levels because of 6 weeks of treatment with alirocumab com-
pared with placebo. Secondary endpoints were the effect of
alirocumab on postprandial leucocyte activation markers CD11b,
CD66b and CD35, total plasma apoB levels and vascular function.
2.4 | Randomization, blinding and treatment
After the first oral fat loading test, patients were randomized 1:1 to
receive subcutaneous injections of either alirocumab 150 mg or
matching placebo (both kindly provided by Regeneron) every 2 weeks
for 6 weeks. Randomization was based on computed generated block
randomization. Both physician and participants were blinded to the allo-
cated strategy. Two weeks after the third injection (6 weeks after the
first oral fat load) patients visited the outpatient clinic for the second oral
fat loading test. Information on the occurrence and type of side effects
of the treatment with either alirocumab or placebo was recorded.
2.5 | Vascular function
Carotid to femoral pulse wave velocity (PWV) and augmentation index
(Aix) were measured and calculated with the SphygmoCor Electronics
Module MM3 and SphygmoCor CvMS Software Suite version 8.0
(AtCor Medical, West Ryde, New South Wales, Australia). The PWV,
which increases at higher aortic stiffness, was measured using a non-
invasive tonometry at the carotid and femoral artery. The distance
between the carotid and femoral artery was measured with a measur-
ing tape. The Aix, adjusted to a heart rate of 75 beats/min, represents
both macrovascular and microvascular function. The radial artery was
used to measure the Aix. Both the PWV and the Aix were measured in
duplicate at each time interval and the mean value is reported.
2.6 | Laboratory measurements
Most clinical chemistry and haematology measurements were carried
out on plasma from freshly drawn blood at the Department of Clinical
Chemistry, Franciscus Gasthuis & Vlietland (Rotterdam, the Nether-
lands) according to standard procedures. C-reactive protein, glucose,
total cholesterol, HDL-C and TG were measured using an Architect
c8000 (Abbott, Chicago, Illinois). LDL-C values were calculated using
the Friedewald formula for TG <4.00 mmol/L. As postprandial TG
concentrations rose above 4.00 mmol/L, no postprandial LDL-C was
calculated. Plasma apoA-I and apoB (which includes both apoB100
and apoB48) were determined by nephelometry using an IMMAGE
instrument with commercially available kits (Beckman Coulter, Miami,
TABLE 1 Baseline characteristics of study participants (n = 12)
Total (n = 12)
Alirocumab
(n = 6)
Placebo
(n = 6)
Age (years) 62.6 ± 7.8 61.5 ± 9.9 63.7 ± 5.6
Body mass index
(kg/m2)
32.8 ± 5.6 31.5 ± 6.0 34.1 ± 5.5
Waist circumference
(cm)
110 ± 21 107 ± 25 113 ± 19
Systolic blood
pressure (mmHg)
134 ± 11 133 ± 12 135 ± 10
Fasting glucose
(mmol/L)
8.5 ± 1.9 8.3 ± 2.3 8.6 ± 1.7
Glycated A1c
(mmol/mol)
65.6 ± 8.7 63.5 ± 7.7 65.5 ± 10.9
Total cholesterol
(mmol/L)
4.0 ± 0.8 3.8 ± 0.7 4.2 ± 0.9
HDL-C (mmol/L) 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.1
LDL-C (mmol/L) 1.9 ± 0.5 1.9 ± 0.5 2.0 ± 0.5
Plasma TG (mmol/L) 1.89
(0.92–2.87)
1.75
(0.86–2.59)
2.64
(1.69–3.59)
ApoAI (g/L) 1.24 ± 0.12 1.23 ± 0.10 1.25 ± 0.14
ApoB (g/L) 0.85 ± 0.20 0.82 ± 0.15 0.89 ± 0.25
ApoB48 (mg/L) 12.9
(4.4–21.4)
9.3
(0.0–19.2)
18.8
(8.2–29.4)
Lipoprotein(a) (mg/L) 120.5
(0.0–376.0)
63.0
(0.0–414.5)
115.0
(0.0–255.5)
Abbreviations: Apo, apolipoprotein; HDL-C, high-density lipoprotein
cholesterol; LDL-C, low-density lipoprotein cholesterol.
Data as mean ± SD or median (interquartile range). There were no
significant differences between treatment groups.
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Florida). Blood cell counts and five-part leucocyte differentiation were
determined using LH750 or DxH analysers (Beckman Coulter).
Haemoglobin A1c (HbA1c) was measured with a G8 analyser (Tosoh,
San Francisco, California).
ApoB48 serum concentrations were quantified using a commercially
available enzyme-linked immunoassay (ELISA) (Shibayagi Co., Ltd.,
Shibukawa, Japan).33 As no commercial quality controls are available for
apoB48, a local internal quality control was pooled according to WHO
recommendations, stored at −80C and then assayed in duplicate on
each plate, in parallel to samples. Paired samples were measured on the
same run.
Free fatty acids (FFAs) were measured by an enzymatic colorimetric
assay (WAKO kit, Fujifilm WAKO Diagnostics, Richmond, Virginia) at the
Division of Endocrinology, Leiden University Medical Center (Leiden, the
Netherlands). Soluble intracellular molecule 1 concentrations were deter-
mined using commercially available ELISA kits (Invitrogen, Carlsbad,
California). Interleukin 1β concentrations were determined using a com-
mercially available ELISA kit (R&D Systems, Minneapolis, Minnesota).
Leucocyte activation markers were measured in EDTA blood as
described in detail before.11,12 Briefly, the staining procedure was
started within 30 min after venepuncture. All measurements were
carried out in triplicate and the mean value is reported. Whole blood
was added to a combination of fluorescein isothiocyanate (FITC)-
conjugated CD66b, phycoerythrin cyanin (PC5)-conjugated CD11b,
phycoerythrin (PE)-conjugated CD35 and phycoerythrin-Texas Red-X-
conjugated CD45. In parallel, blood was added to a combination of
FITC, and PC5- and PE-conjugated mouse IgG1 as isotype controls to
correct for non-specific binding. All antibodies were from Beckman
Coulter, except for CD35-PE (BD Bioscience, Franklin Lakes, New Jer-
sey). Cells were incubated for 15 min in the dark at room temperature.
Erythrocytes were subsequently lysed by adding isotonic erythrocyte
lysing solution (in mol/L: 0.19 ammonium chloride, 0.01 potassium
hydrogen carbonate, 0.12 EDTA, pH 7.2) for 15 min. An FC500 flow
cytometer and Kaluza 1.5a (Beckman Coulter) were used for measure-
ment and analysis. Lymphocytes, monocytes and neutrophil
granulocytes were identified based on their side scatter and the level
of CD45 on their surface. The fluorescent intensity of each cell popula-
tion was expressed as the mean fluorescent intensity in arbitrary units.
Lipoprotein profiles were obtained using density gradient ultracen-
trifugation34 for time-points t = 0, t = 4 and t = 8 h. KBr was added to
plasma (0.35 g/mL) to obtain a density of 1.26 g/mL. Of this plasma,
1 mL was placed in an ultracentrifuge tube and 19 mL of KBr solutions
F IGURE 1 Total cholesterol, HDL-
cholesterol, triglycerides, apoB48, and
total apoB concentrations after an oral
fat load test. Mean ± SEM of total
cholesterol (A), HDL-cholesterol (B),
triglycerides (C), apoB48 (D) and apoB
(E) at baseline (open square) and after
treatment (closed square) with
alirocumab and at baseline (open
circle) and after treatment (closed
circle) with placebo during an oral fat
load test. *P <0.05 versus placebo for
treatment with alirocumab. There
were no significant differences at
baseline or after treatment for the
placebo group. Apo, apolipoprotein;
HDL, high-density lipoprotein
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of 1.21, 1.10, 1.063, 1.04 and 1.02 g/mL in physiological salt were lay-
ered successively on top, followed by 1 mL of water. Samples were
centrifuged at 207 000 g for 18 h at 4C using a SW41 rotor in a L-70
Beckman ultracentrifuge (Beckman Instruments, Indianapolis, Indiana).
After each run, the density gradient was fractionated from the bottom
into 250 μL fractions. Lipoproteins were separated based on density.
VLDL, chylomicrons and large remnants were recovered in the 1.02 g/
mL range; this fraction is designated uVLDL. LDL was recovered in
fractions with densities ranging from 1.04 to 1.063 g/mL; this fraction
is designated uLDL. Fractions with densities ranging from 1.063 to
1.21 g/mL were considered to constitute HDL and designated uHDL.
(NB: ‘u’ depicts measurements after serum ultracentrifugation.).
Cholesterol, TG and apoB in the fractions were measured using a
Selectra E (DDS Diagnostic system, Istanbul, Turkey).
2.7 | Statistical analysis
Data are given as mean ± SD for normally distributed variables,
median (interquartile range) for variables with skewed distribution
(plasma TG, apoB48, C-reactive protein and PWV) and number
(%) for categorical variables. In all figures, data are presented as
mean ± SEM.
The main treatment effect (P-model) of alirocumab versus placebo
on outcome values between pre- and post-treatment levels was
tested with ANCOVA with the post-treatment concentrations as the
dependent variable, pretreatment concentrations as covariate and
treatment group as fixed effect. Data were presented as median
change in percentage of outcome value compared with baseline by
alirocumab versus placebo.
Differences within groups before and after treatment (for both
fasting and postprandial concentrations) were determined by the
paired t-test or Wilcoxon matched pair signed rank test, depending
on the skewness of the distribution. Differences between groups
were determined by the independent Student's t-test or Mann–
Whitney U-test, where appropriate. All postprandial responses were
calculated by the area under the curve (AUC), using the trapezoidal
rule with GraphPad Prism version 5.0 (Los Angeles, California). Incre-
mental AUC (iAUC) was calculated after correction for fasting
concentrations.
TABLE 3 Changes (area under the curve) in postprandial lipid and cholesterol levels
Alirocumab (n = 6) Placebo (n = 6)
Between group
difference
Baseline Week 6
% Change
from
baseline Baseline Week 6
% Change
from
baseline
Median %
change
from
baseline P-model
Total cholesterol
AUC (mmol/L 8 h) 31.5 ± 5.7 19.8 ± 1.7* −37.1 34.2 ± 6.5 32.0 ± 4.7 −6.4 −28.2 <0.001
iAUC (mmol/L 8 h) 1.5 ± 0.6 0.9 ± 0.6* −38.4 1.1 ± 0.9 1.3 ± 1.1 +14.2 −19.2 0.01
HDL-C
AUC (mmol/L 8 h) 8.1 ± 1.9 8.7 ± 2.1 +7.4 7.4 ± 1.0 7.1 ± 0.9 −4.1 +4.2 0.04
iAUC (mmol/L 8 h) 0.3 ± 0.3 0.6 ± 0.2* +97.6 0.3 ± 0.2 0.3 ± 0.3 +1.4 +23.2 0.03
Total TG
AUC (mmol/L 8 h) 25.8 (16.4–35.2) 18.0 (14.5–21.5) −30.2 36.8 (21.8–51.8) 35.0 (23.8–46.2) −4.9 −26.3 0.01
iAUC (mmol/L 8 h) 8.6 (3.2–11.8) 6.2 (4.6–7.8) −29.4 11.8 (4.1–19.4) 12.4 (6.1–18.7) +0.8 −21.4 0.04
ApoB
AUC (g/L 8 h) 6.8 ± 1.1 3.4 ± 0.8* −50.1 7.1 ± 1.3 6.8 ± 1.0 −4.3 −48.6 <0.001
iAUC (g/L 8 h) 0.2 ± 0.2 0.1 ± 0.2 −39.3 0.2 ± 0.1 0.2 ± 0.2 −2.5 −28.3 0.04
ApoB48
AUC (mg/L 8 h) 105.6
(43.5–167.7)
69.2
(38.3–100.1)*
−34.5 207.5
(147.5–267.5)
201.8
(83.1–320.5)
−3.7 −55.7 0.046
iAUC (mg/L 8 h) 15.8 (0.0–33.5) 9.7 (4.0–15.4) −28.8 27.0 (0.0–63.0) 30.5 (22.2–38.8) +4.7 −26.8 0.02
Free fatty acids
AUC (mmol/L 8 h) 6.5 ± 2.4 5.9 ± 1.9 −9.2 6.7 ± 1.1 6.7 ± 2.4 −0.9 −9.8 0.34
iAUC (mmol/L 8 h) 0.7 ± 1.3 0.8 ± 0.9 +1.3 0.8 ± 0.8 0.8 ± 1.0 +2.3 +1.3 0.53
Abbreviations: Apo, apolipoprotein; AUC, area under the curve; HDL, high-density lipoprotein; iAUC, incremental area under the curve.
Data as mean ± SD or median (interquartile range). P-model by ANCOVA with post-treatment levels as dependent variable and pretreatment levels as
covariable.
*P <0.05 versus baseline.
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Statistical analysis was carried out with PASW statistics version
25.0 (IBM SPSS Statistics, New York). P <0.05 (two-tailed) was consid-
ered statistically significant.
3 | RESULTS
3.1 | Baseline characteristics
Twelve eligible patients were randomized to either alirocumab (n = 6)
or placebo (n = 6). The mean age was 62.6 ± 7.8 years, all were on
statin treatment with a mean plasma LDL-C of 1.9 ± 0.5 mmol/L, and
median plasma TG concentrations of 1.89 (0.93–2.87) mmol/L. Addi-
tional baseline characteristics are shown in Table 1. No serious
adverse events were recorded.
3.2 | Effect of alirocumab on fasting lipid
concentrations
Table 2 shows the fasting and postprandial lipid concentrations before
and after treatment. Six weeks of alirocumab treatment significantly
decreased fasting concentrations of total cholesterol (median change
of −28.2%; P-model <0.001), LDL-C (−39.5%; P <0.001), plasma TG
(−24.7%; P = 0.02), plasma apoB (−50.7%; P = <0.001) and apoB48
(−35.9%; P = 0.04) compared with placebo. Alirocumab did not signifi-
cantly affect HbA1c, FFA or glucose concentrations.
3.3 | Effects of alirocumab on postprandial plasma
triglyceride and apolipoprotein B48 concentrations
Alirocumab resulted in a significantly reduced plasma TG-AUC
(median change of −26.3%; P-model 0.006) and apoB48-AUC
response (−55.7%; P = 0.046) compared with placebo (Figure 1 and
Table 3). In addition, reductions in plasma TG-iAUC (−21.4%;
P = 0.04) and apoB48-iAUC (−26.8; P = 0.02) compared with placebo
were found. Furthermore, total cholesterol-AUC (−28.2%; P <0.001),
plasma apoB-AUC (−48.6%; P <0.001) and HDL-C-AUC (+4.2%;
P = 0.04) changed after alirocumab, while FFA remained unaffected.
3.4 | Effects of alirocumab on lipoprotein profiles
Compared with placebo, alirocumab reduced fasting uVLDL-TG
(median change −29.1%; P-model 0.04), uVLDL-C (−41.2%, P <0.001)
and uVLDL-apoB (−65.7%; P <0.001). Reductions were also observed
for fasting uLDL-TG (−25.6%; P = 0.003), uLDL-C (−39.9%; P <0.001)
and uLDL-apoB (−44.1%; P <0.001) (Table 2 and Figure S1; see
Supporting Information).
In addition, after 4 and 8 h, significant reductions of uVLDL-TG,
uVLDL-C, uVLDL-apoB and uLDL-TG, uLDL-C and uLDL-apoB were
observed (see Table S1; see Supporting Information).
3.5 | Effects of alirocumab on inflammatory
parameters and vascular function
Alirocumab did not significantly affect fasting or postprandial
leucocyte counts or leucocyte activation markers (see Tables S2 and
S3, Figure S2; see Supporting Information).
Fasting PWV was reduced by alirocumab compared with placebo
(−7.9%; P = 0.03); however, no significant differences in postprandial
changes of PWV were observed (Figure 2 and Table S3; see
Supporting Information). No significant changes were observed
in Aix.
4 | DISCUSSION
In this proof-of-concept study, we investigated the effects of
alirocumab on postprandial concentrations of lipids and lipoproteins
and on postprandial inflammation in male patients with T2DM on
intensive insulin treatment. Alirocumab significantly reduced fasting
plasma TG and apoB48 concentrations as well as the postprandial
plasma response of TG and apoB48. Furthermore, significant reduc-
tions in the TG, cholesterol and apoB fractions of uLDL and uVLDL
were observed.
F IGURE 2 PWV and pulse wave Aix after an oral fat load test.
Mean ± SEM of PWV (A) and pulse wave Aix (B) at baseline (open
square) and after treatment (closed square) with alirocumab and at
baseline (open circle) and after treatment (closed circle) with placebo
during an oral fat load test. No significant postprandial differences
were observed between groups at baseline or after treatment. Aix,
augmentation index; PWV, pulse wave velocity
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Two previous studies in healthy subjects did not find changes in
fasting TG or postprandial plasma TG responses by PCSK9 inhibi-
tion.20,29 The most likely explanation for the different finding is the
fact that our study included only patients with T2DM. Patients with
diabetes are characterized by an increased production and an
impaired clearance of both chylomicrons and VLDL,35 leading to a
state of competition in the clearance of these particles. The improved
clearance of these TG-rich lipoproteins (TRL) by PCSK9 inhibition
might only be revealed when the system is “under pressure”, such as
in patients with diabetes. To our knowledge, this is the first study
investigating the effect of PCSK9 on postprandial lipid metabolism in
patients with T2DM.
We propose that the reduction in fasting and postprandial plasma
TG as observed here is partly caused by increased catabolic efficacy
because of reduced competition at the level of the lipolytic enzymes
involved in the clearance of TRL [lipoprotein lipase (LPL) and hepatic6
lipase]. As the majority of TGs reside in chylomicrons and VLDL, the
strong reduction of these TRL resulted in reduced levels of plasma TGs.
PCSK9 inhibition leads to upregulation of the hepatic LDLR, which
besides LDL particles also recognizes and binds apoE-containing parti-
cles, including TRL remnants.25 Therefore, upregulation of the LDLR
leads to increased removal of LDL and enhanced direct uptake of rem-
nants (both chylomicron and VLDL remnants). Chylomicrons normally
compete with VLDL for the same lipolytic pathways, leading to accumu-
lation of endogenous VLDL in the postprandial state.36,37 An increased
TRL clearance should therefore result in increased LPL-mediated lipoly-
sis because of lower competition. In the present study, we found
decreased fasting and postprandial (at t = 4 h) concentrations of
uVLDL-TG and uVLDL-C. This is in line with a report by Chan et al,
who previously described that PCSK9 inhibition leads to decreased
postprandial VLDL-apoB100.20
In addition, there is evidence showing that PCKS9 inhibition is
not only involved in the LDLR expression, but also leads to reduced
degradation of the VLDL receptor.38,39 The VLDL receptor plays an
important role in postprandial lipoprotein metabolism by enhancing
the LPL-mediated TG hydrolysis,40 which could enhance the TG-
lowering effects of alirocumab.
The reduction of postprandial lipaemia by PCSK9 inhibition, as
shown in this study, could be an important factor in the reduction of
the excess CVD risk in patients with T2DM;41 in particular, because
there is an abundance of evidence that the non-fasting TGs, which are
related to chylomicron remnants, are associated with higher risk of
CVD compared with fasting LDL-C.9 In addition, it has been shown
that chylomicron remnants have a longer retention time in the arterial
wall compared with LDL.42 As arterial wall retention of lipoproteins
results in atherosclerosis,43 reductions of these postprandial lipopro-
teins could be beneficial in terms of cardiovascular risk.
Reductions in postprandial concentrations of apoB48 have been
found in studies evaluating the postprandial lipoprotein metabolism
with HMG-CoA reductase inhibitors (statins) in patients with diabetes.
For example, Battula et al showed that cerivastatin reduced TGs and
cholesterol in the TRL fractions of patients with diabetes.21
Besides the effects on lipaemia and inflammation, we also
explored the effects of PCSK9 inhibition on vascular function. It has
been shown that an oral fat load acutely impairs vascular func-
tion.13,15,16 Furthermore, several trials have shown that an interven-
tion with statins improves vascular function44,45 and we have
described an effect on postprandial leucocyte activation.46 Our group
has published repeatedly on this postprandial inflammation and the
effects on postprandial vascular function.47,48 In the present trial only
a reduction in fasting PWV was found and no postprandial changes
were observed. This can mainly be explained by the fact that our study
group was small and the variance in measurements of both PWV and
Aix was relatively large, particularly in the postprandial period. This
may also explain the lack of effects of inflammatory parameters.
Importantly, we observed a non-significant trend for higher
fasting TG and apoB48 concentrations in the placebo group versus
the alirocumab group. This could have affected our results, as fasting
plasma TG levels are an important determinant of the postprandial TG
response.49,50 To address this issue, we corrected for baseline levels
in our main comparison between groups and used postprandial
responses for all variables. The incremental data are in line with the
unadjusted results.
In conclusion, this study suggests that in male patients with T2DM
who are on an intensive insulin regimen, inhibition of PCSK9 with
alirocumab resulted in a decreased postprandial plasma TG response
because of lower chylomicrons and their remnants, but also in a decrease
in other lipoprotein fractions. This mechanism may contribute to the
observed improved vascular function described here and the studies
showing reductions in cardiovascular events in patients with T2DM on
PCSK9 inhibitors, in addition to the potent effects on LDL-C.
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